| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 84 |
| 1 | NIVOLUMAB | 40 |
| 2 | CARBOPLATIN | 28 |
| 3 | ALEMTUZUMAB | 24 |
| 4 | IPILIMUMAB | 22 |
| 5 | PACLITAXEL | 19 |
| 6 | PACLITAXEL (AIBUMIN-BOUND) | 18 |
| 7 | TRASTUZUMAB | 16 |
| 8 | CISPLATIN | 15 |
| 9 | CAPECITABINE | 14 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CASTOR OIL | 2 | 0.0104 |
| 1 | TALIGLUCERASE ALFA | 1 | 0.0017 |
| 2 | TALIMOGENE LAHERPAREPVEC | 2 | 0.0013 |
| 3 | ALEMTUZUMAB | 24 | 0.0012 |
| 4 | CLINDAMYCIN PHOSPHATE | 6 | 0.0011 |
| 5 | DOSTARLIMAB | 2 | 0.0008 |
| 6 | ALDESLEUKIN | 1 | 0.0008 |
| 7 | FINGOLIMOD HYDROCHLORIDE | 4 | 0.0008 |
| 8 | PEMBROLIZUMAB | 84 | 0.0008 |
| 9 | ROPEGINTERFERON ALFA-2B | 1 | 0.0005 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD52-directed Cytolytic Antibody [EPC] | 24 | 0.0012 |
| 1 | Lymphocyte Growth Factor [EPC] | 1 | 0.0008 |
| 2 | Interferon alfa-2b [EPC] | 1 | 0.0005 |
| 3 | CTLA-4-directed Blocking Antibody [EPC] | 23 | 0.0005 |
| 4 | Programmed Death Ligand-1 Blocker [EPC] | 10 | 0.0005 |
| 5 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 40 | 0.0004 |
| 6 | Sphingosine 1-phosphate Receptor Modulator [EPC] | 4 | 0.0003 |
| 7 | alpha-1 Adrenergic Agonist [EPC] | 1 | 0.0002 |
| 8 | HER2/neu Receptor Antagonist [EPC] | 16 | 0.0002 |
| 9 | Antifibrinolytic Agent [EPC] | 2 | 0.0002 |